PBH · Prestige Consumer Healthcare Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · PBH

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$1.09B	$1.14B	$1.13B	$1.13B	$1.09B	$943.37M
Cost of Revenue	$493.13M	$503.30M	$500.91M	$502.43M	$466.17M	$395.89M
Gross Profit	$595.58M	$634.46M	$624.45M	$625.29M	$620.65M	$547.47M
R&D	-	-	-	-	-	-
SG&A	$116.45M	$108.21M	$106.15M	$107.35M	$108.52M	$85.54M
Total Operating Expenses	$286.17M	$297.69M	$282.02M	$647.71M	$290.73M	$250.07M
D&A	$31.27M	$30.17M	$30.68M	$32.63M	$32.09M	$30.16M
Operating Income	$309.41M	$336.77M	$342.43M	($22.41M)	$329.92M	$297.40M
Interest Expense	-	$1.80M	$5.20M	$69.16M	$64.29M	$82.33M
Income Tax	$67.19M	$69.58M	$66.69M	($11.61M)	$57.08M	$39.43M
Net Income	$190.30M	$214.60M	$209.34M	($82.31M)	$205.38M	$164.68M
EPS - Basic	$3.93	$4.32	$4.21	($1.65)	$4.09	$3.28
EPS - Diluted	$3.91	$4.29	$4.17	($1.65)	$4.04	$3.25

Balance Sheet

Line item	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Cash & Equivalents	$63.87M	$97.88M	$46.47M	$58.49M	$27.18M	$32.30M
Accounts Receivable	$191.92M	$194.29M	$176.78M	$167.02M	$139.33M	$114.67M
Inventory	$159.13M	$147.71M	$138.72M	$162.12M	$120.34M	$114.96M
Accounts Payable	$22.79M	$18.93M	$38.98M	$62.74M	$55.76M	$45.98M
Current Assets	$431.48M	$448.33M	$375.04M	$391.74M	$293.27M	$269.83M
Total Assets	$3.49B	$3.40B	$3.32B	$3.35B	$3.67B	$3.43B
Current Liabilities	$120.92M	$106.62M	$117.05M	$160.72M	$143.42M	$122.14M
Long-term Debt	$993.95M	$992.36M	$1.13B	$1.35B	$1.48B	$1.48B
Total Liabilities	$1.61B	$1.57B	$1.66B	$1.91B	$2.09B	$2.07B
Stockholders' Equity	$1.89B	$1.83B	$1.66B	$1.45B	$1.58B	$1.36B
Retained Earnings	$1.75B	$1.56B	$1.34B	$1.13B	$1.21B	$1.01B

Cash Flow

Line item	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Operating Cash Flow	$257.63M	$251.51M	$248.93M	$229.72M	$259.92M	$235.61M
Investing Cash Flow	($136.84M)	($17.45M)	($20.11M)	($11.58M)	($256.51M)	($22.24M)
Financing Cash Flow	($156.06M)	($182.07M)	($241.01M)	($185.85M)	($7.57M)	($279.42M)
CapEx	$11.18M	$8.22M	$9.55M	$7.78M	$9.64M	$22.24M
Free Cash Flow	$246.45M	$243.29M	$239.38M	$221.93M	$250.28M	$213.36M

Ratios

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Profitability
Gross margin	54.7%	55.8%	55.5%	55.4%	57.1%	58.0%
Operating margin	28.4%	29.6%	30.4%	-2.0%	30.4%	31.5%
EBITDA margin	31.3%	32.3%	33.2%	0.9%	33.3%	34.7%
Net margin	17.5%	18.9%	18.6%	-7.3%	18.9%	17.5%
Free cash flow margin	22.6%	21.4%	21.3%	19.7%	23.0%	22.6%
FCF / Net income	1.30	1.13	1.14	-2.70	1.22	1.30
R&D / Revenue	-	-	-	-	-	-
SG&A / Revenue	10.7%	9.5%	9.4%	9.5%	10.0%	9.1%
Effective tax rate	26.1%	24.5%	24.2%	-	21.7%	19.3%
Return on assets	5.4%	6.3%	6.3%	-2.5%	5.6%	4.8%
Return on equity	10.1%	11.7%	12.6%	-5.7%	13.0%	12.1%
Return on invested capital	7.9%	9.0%	9.3%	-0.6%	8.5%	8.5%
Liquidity
Current ratio	3.57	4.20	3.20	2.44	2.04	2.21
Quick ratio	2.25	2.82	2.02	1.43	1.21	1.27
Cash ratio	0.53	0.92	0.40	0.36	0.19	0.26
Leverage
Debt / Equity	0.53	0.54	0.68	0.93	0.94	1.09
Debt / Assets	0.28	0.29	0.34	0.40	0.40	0.43
Debt / EBITDA	2.92	2.70	3.02	131.81	4.08	4.52
Interest coverage	-	187.1x	65.9x	-0.3x	5.1x	3.6x
Equity multiplier	1.85	1.85	2.00	2.32	2.33	2.52
Liabilities / Assets	0.46	0.46	0.50	0.57	0.57	0.60
Efficiency
Asset turnover	0.31	0.33	0.34	0.34	0.30	0.28
Inventory turnover	3.10	3.41	3.61	3.10	3.87	3.44
Days sales outstanding	64d	62d	57d	54d	47d	44d
Days inventory outstanding	118d	107d	101d	118d	94d	106d
Days payable outstanding	17d	14d	28d	46d	44d	42d
Cash conversion cycle	165d	156d	130d	126d	97d	108d
Valuation
P / E	15.2x	20.0x	17.4x	-	13.1x	13.6x
P / B	1.5x	2.3x	2.2x	2.2x	1.7x	1.6x
P / S	2.7x	3.8x	3.2x	2.8x	2.5x	2.4x
EV / EBITDA	11.2x	14.2x	12.7x	432.1x	11.4x	11.2x
Growth
Revenue growth (YoY)	-4.3%	1.1%	-0.2%	3.8%	15.2%	-2.0%
Revenue CAGR (3y)	-1.2%	1.5%	6.1%	5.4%	1.4%	-3.2%
Revenue CAGR (5y)	2.9%	3.4%	1.6%	1.6%	4.3%	3.2%
Gross profit growth (YoY)	-6.1%	1.6%	-0.1%	0.7%	13.4%	-0.9%
Operating income growth (YoY)	-8.1%	-1.7%	-	-	10.9%	2.1%
Net income growth (YoY)	-11.3%	2.5%	-	-	24.7%	15.7%
EPS growth (YoY)	-8.9%	2.9%	-	-	24.3%	16.9%
EPS CAGR (3y)	-	2.0%	8.7%	-	-	-20.0%
EPS CAGR (5y)	3.8%	9.1%	-	-	25.5%	11.6%
FCF growth (YoY)	1.3%	1.6%	7.9%	-11.3%	17.3%	5.3%
FCF CAGR (5y)	2.9%	3.7%	6.0%	2.4%	11.6%	4.6%
Book value growth (YoY)	2.9%	10.9%	14.4%	-8.3%	16.1%	16.0%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2026-03-31.

Business segments

$1.09B total

North American OTCHealthcare$913.58M · 83.9%

International OTCHealthcare$175.13M · 16.1%

Product / service

$2.00B total

Product$1.08B · 54.2%

Womens Health$205.05M · 10.2%

Gastrointestinal$179.30M · 9.0%

Eye And Ear Care$126.13M · 6.3%

Dermatologicals$116.62M · 5.8%

Analgesics$108.30M · 5.4%

Oral Care$86.96M · 4.3%

Cough And Cold$76.88M · 3.8%

Other Otc$14.34M · 0.7%

Product And Service Other$3.96M · 0.2%

Geographic

$1.09B total

US$850.41M · 78.1%

Non Us$238.29M · 21.9%

Stability scores

Altman Z′

FY 2026 · bankruptcy risk

1.57

Grey zone

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2026 · 9-point quality

4/9

Neutral

✓Net income positive
✓Operating cash flow positive
✗ROA improved YoY
✓Cash flow > net income
✗Long-term debt decreased
✗Current ratio improved
✓No share dilution
✗Gross margin improved
✗Asset turnover improved

Peer comparison

Same SIC group: Pharmaceutical Preparations

Company	Revenue (last FY)	Net margin	ROE
LLY	$65.18B	31.7%	77.8%
UTHR	$3.18B	41.9%	18.8%
PFE	$62.58B	12.4%	9.0%
ZTS	$9.47B	28.2%	80.2%
VRTX	$12.00B	32.9%	21.2%

Comparing Prestige Consumer Healthcare Inc. against the 5 most active filers in the same SIC group.